Anika Therapeutics Stock
Price
Target price
?
?
-0.560%
-0.1
-0.560%
-
08:02 / Frankfurt
WKN: 889120 / Symbol: ANIK / Name: Anika / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Anika Therapeutics Stock
The price for the Anika Therapeutics stock decreased slightly today. Compared to yesterday there is a change of -€0.100 (-0.560%).
For the coming years our community has positive and negative things to say abot the Anika Therapeutics stock. Criterium "Brand" gathered the most positive votes but regarding "EBIT growth" there were negative voices in the community.
Pros and Cons of Anika Therapeutics in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Anika Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Anika Therapeutics | -0.560% | 9.202% | 33.835% | 138.926% | 122.500% | 5.952% | -48.555% |
| Heron Therapeutics Inc. | -0.480% | -32.607% | -20.601% | -75.641% | -73.914% | -80.497% | -96.899% |
| Evolus Inc | -0.400% | 27.435% | 22.133% | 31.811% | 28.183% | -21.506% | -21.506% |
| Rhythm Pharmaceuticals | -0.990% | 6.878% | 7.447% | 24.691% | 8.021% | 313.934% | 763.248% |
Comments
Anika Therapeutics (ANIK) had its "buy" rating reaffirmed by B. Riley Financial, Inc..
Show more
Ratings data for ANIK provided by MarketBeat
Anika Therapeutics (ANIK) had its price target raised by Barrington Research from $16.00 to $17.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ANIK provided by MarketBeat
Anika Therapeutics (NASDAQ:ANIK) had its price target raised by analysts at Barrington Research from $15.00 to $16.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ANIK provided by MarketBeat
News
Anika Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Anika Therapeutics Inc.? Here are five stocks we like better.
- Second-quarter performance strengthened: Revenue rose 16% year over year to $32.6 million, while gross
